millennium pharmaceuticals, inc. what happened next?

12
Millennium Pharmaceuticals, Inc. What happened next?

Upload: rosemary-parrish

Post on 04-Jan-2016

219 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Millennium Pharmaceuticals, Inc. What happened next?

Millennium Pharmaceuticals, Inc.

What happened next?

Page 2: Millennium Pharmaceuticals, Inc. What happened next?

Should they do the deal?

Yes, because: Long-term revenues ($220 MM plus) Firm growth (1000 to 1300

employees) Further commitment to agribusinesss Software development and

documentation

Page 3: Millennium Pharmaceuticals, Inc. What happened next?

Should they do the deal?

No, because: 1000 employee threshold Already spread thin Agribusiness is not the long term goal Lundberg’s lack of preparation raises

commitment and understanding concerns

Page 4: Millennium Pharmaceuticals, Inc. What happened next?

Should they do the deal?

Page 5: Millennium Pharmaceuticals, Inc. What happened next?

Did they do the deal?

No, they did not. Review of the Millennium website

indicates that they have not done any agribusiness deals since Monsanto.

Page 6: Millennium Pharmaceuticals, Inc. What happened next?

Millennium –strategic direction

Speed drug development through technology Serial steps in parallel “Front load” the discovery process

Strategic alliancesBecome an integrated pharmaceutical firm

Page 7: Millennium Pharmaceuticals, Inc. What happened next?

How have they done?

Speed the process According to an article from

TheStreet.com (July 17, 2002), to date, Millennium has only one internally developed drug, an experimental metabolic drug in early Phase I testing, in clinical trials.

Page 8: Millennium Pharmaceuticals, Inc. What happened next?

How have they done?

Strategic alliances Since the Bayer deal, Millennium has

successfully completed eight (8) major strategic alliances. These alliances have covered a variety of

strategic areas, to help Millennium internalize new skills.

In addition to the alliances, they have completed at least one major acquisition, Cor Therapeutics.

Page 9: Millennium Pharmaceuticals, Inc. What happened next?

How have they done?

Become an integrated pharmaceutical firm: Simply put – they have not. Their

current revenue leading drug – Integrilin – came as part of the Cor Therapeutics acquisition and is marketed in conjunction with Schering-Plough.

Page 10: Millennium Pharmaceuticals, Inc. What happened next?

How have they done financially?

Market cap of ~$3 Billion2002 expected sales of $300 MillionSecond quarter loss (excluding charges and gains) $0.16 / share vs. $0.19 (analyst expected)Drug pipeline – “Viable and growing” TheStreet.com July 17, 2002

Page 11: Millennium Pharmaceuticals, Inc. What happened next?

How have they done financially?

Page 12: Millennium Pharmaceuticals, Inc. What happened next?

Core Competencies(then & now)

PlatformProductivity InnitiativeMergers and AlliancesFranchise AreasPeople Source Millennium.com July 31, 2002